Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Addenbrookes Hospital, Cambridge, United Kingdom

Survival: 6.5 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United Kingdom
City/State/Province: Cambridge
Hospital: Addenbrookes Hospital
Journal: Link
Date: 10/2010

This study involved 34 patients with metastatic melanoma. The median patient age was 62 years and 62% were male.

Patients were given the biologic agent vatalanib, a tyrosine kinase inhibitor. This drug functions as an anti-angiogenesis agent and inhibits blood vessel growth in tumors.

The highest toxicity grade reported was 3, mostly consisting of hypertension and elevated liver enzymes. Other reported toxicities included proteinuria, dizziness, fatigue, and nausea.

The median overall survival reported in this study was 6.5 months. Median progression-free survival was 1.8 months.

This study was partially supported by Bayer Schering Pharma, makers of vatalanib.

Correspondence: Dr. Pippa G. Corrie; email:

E-mail to a Friend Email Physician More Information